Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
作者信息
Choughule A, Sharma R, Trivedi V, Thavamani A, Noronha V, Joshi A, Desai S, Chandrani P, Sundaram P, Utture S, Jambhekar N, Gupta S, Aich J, Prabhash K, Dutt A
机构信息
Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
1] Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India [2] Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, India.
出版信息
Br J Cancer. 2014 Nov 25;111(11):2203-4. doi: 10.1038/bjc.2014.401. Epub 2014 Aug 12.
Abstract
摘要
相似文献
1
Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Br J Cancer. 2014 Nov 25;111(11):2203-4. doi: 10.1038/bjc.2014.401. Epub 2014 Aug 12.
2
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Am J Clin Oncol. 2015 Feb;38(1):33-40. doi: 10.1097/COC.0b013e318287bb23.
3
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
J Thorac Oncol. 2010 Feb;5(2):169-78. doi: 10.1097/JTO.0b013e3181c8cbd9.
4
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10.
5
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
J Exp Clin Cancer Res. 2011 Mar 17;30(1):30. doi: 10.1186/1756-9966-30-30.
6
Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
J Cancer Res Clin Oncol. 2014 Jul;140(7):1087-95. doi: 10.1007/s00432-014-1671-x. Epub 2014 Apr 13.
7
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4.
8
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Oncogene. 2009 Aug;28 Suppl 1(Suppl 1):S24-31. doi: 10.1038/onc.2009.198.
9
ALK, lung cancer, and personalized therapy: portent of the future?
J Natl Cancer Inst. 2010 May 19;102(10):672-5. doi: 10.1093/jnci/djq184. Epub 2010 May 11.
10
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4.
引用本文的文献
1
The complex journey of targeting RAS in oncology.
BMC Cancer. 2025 Jul 1;25(1):1053. doi: 10.1186/s12885-025-14033-y.
2
Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring 21 L858R mutation.
Glob Med Genet. 2025 Feb 19;12(2):100051. doi: 10.1016/j.gmg.2025.100051. eCollection 2025 Jun.
3
The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer.
ESMO Open. 2025 Apr;10(4):104479. doi: 10.1016/j.esmoop.2025.104479. Epub 2025 Mar 14.
4
A Case of Non-Small Cell Lung Cancer with Mutually Exclusive and Mutations.
Curr Issues Mol Biol. 2025 Jan 20;47(1):66. doi: 10.3390/cimb47010066.
5
Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
PLoS One. 2022 Oct 18;17(10):e0276161. doi: 10.1371/journal.pone.0276161. eCollection 2022.
6
Targeting Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.
Front Oncol. 2022 Feb 16;12:796832. doi: 10.3389/fonc.2022.796832. eCollection 2022.
7
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Oncotarget. 2021 Mar 16;12(6):578-588. doi: 10.18632/oncotarget.27905.
8
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.
Front Oncol. 2020 Dec 10;10:610923. doi: 10.3389/fonc.2020.610923. eCollection 2020.
9
A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Mol Med. 2020 Jun 17;26(1):59. doi: 10.1186/s10020-020-00183-1.
10
Impact of smoking on frequency and spectrum of and mutations in treatment naive Indonesian lung cancer patients.
Lung Cancer (Auckl). 2019 Jun 17;10:57-66. doi: 10.2147/LCTT.S180692. eCollection 2019.
本文引用的文献
1
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Br J Cancer. 2014 May 27;110(11):2812-20. doi: 10.1038/bjc.2014.210. Epub 2014 Apr 17.
2
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.
PLoS One. 2013 Oct 4;8(10):e76164. doi: 10.1371/journal.pone.0076164. eCollection 2013.
3
EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy.
PLoS One. 2013 Apr 19;8(4):e61561. doi: 10.1371/journal.pone.0061561. Print 2013.
4
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.
5
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.
6
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4.
7
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
Anticancer Res. 2010 May;30(5):1667-71.
8
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
Lung Cancer. 2010 Sep;69(3):272-8. doi: 10.1016/j.lungcan.2009.11.020. Epub 2009 Dec 22.
9
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
10
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.
Zotero 插件